摘要
Abstract
Objective To discuss the clinical effects and adverse reaction of rituximab combined with CHOP chemo￣therapy treating B￣cell non￣Hodgkin lymphoma. Methods 96 patients with CD20 positive B￣cell non￣Hodgkin lymphoma were chosen to divide into CHOP combination group and CHOP group.The patients in CHOP combination group were treated with rituximab combined with CHOP chemotherapy.The patients in CHOP group were treated with CHOP chemotherapy.The effects and adverse reaction in two groups were evaluated after 4 courses of treatment. Results The effective rate of CHOP combination group was 90.0% which was higher than 72.4% of CHOP group,the difference was statistically signifi￣cant (P<0.05).The difference of adverse reaction between two groups was not statistically significant (P>0.05).The pro￣gress free survival ( PFS) of CHOP combine group after 1 year,3 years,5years were 81.6%,61.2%,26.5% respectively,the overall survival (OS) were 89.8%,65.3%,30.6% respectively.The PFS and OS in CHOP combine group were obviously higher than CHOP group,and the differences of PFS and OS between two groups after 1 year,3 years,5years were statisti￣cally significant( P<0.05) . Conclusion The treatment of rituximab combined with CHOP chemotherapy for B￣cell non￣Hodgkin lymphoma could improve the clinical effects and the quality of long￣term survival,and it will not increase adverse reaction caused by combination chemotherapy.关键词
利妥昔单抗/非霍奇金淋巴瘤/CHOP方案Key words
rituximab/non-Hodgkin lymphoma/CHOP chemotherapy分类
医药卫生
